Page last updated: 2024-10-27

gabapentin and Uremia

gabapentin has been researched along with Uremia in 24 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Uremia: A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.

Research Excerpts

ExcerptRelevanceReference
"Gabapentin and doxepin are well-known treatments of uremic pruritus in hemodialysis patients but no head-to-head studies were conducted to date."9.34Comparison of gabapentin and doxepin in the management of uremic pruritus: A randomized crossover clinical trial. ( Ammoury, A; Bachour, J; Haber, R; Habr, L; Joubran, N; Khoury, F; Maacaron, T; Salloum, A, 2020)
" dexchlorpheniramine in reducing uremic pruritus."9.27Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial. ( Abbade, LP; Gobo-Oliveira, M; Miot, HA; Ogata, MS; Pigari, VG; Ponce, D, 2018)
"Gabapentin relieved itching in 47 patients (66%)."9.16Uraemic pruritus: relief of itching by gabapentin and pregabalin. ( Baharani, J; Dasgupta, I; Rayner, H; Smith, S; Suresh, V, 2012)
"Desloratadine provides significant relief of uremic pruritus compared with no therapy."9.16Uremic pruritus in hemodialysis patients: treatment with desloratidine versus gabapentin. ( Barrón, B; Lauxmann, JE; Marquez, D; Martinatto, C; Novoa, PA; Orías, M; Peixoto, AJ; Ramonda, C; Romero, CA; Vukelic, VL, 2012)
"Gabapentin is an effective agent in treating uremic pruritus."9.14Gabapentin and uremic pruritus in hemodialysis patients. ( Eskandari, D; Ganji, MR; Khashayar, P; Meysamie, AP; Razeghi, E; Togha, M, 2009)
"Our study shows that gabapentin is safe and effective for treating uraemic pruritus in haemodialysis patients."9.11Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. ( Celiker, H; Gunal, AI; Gunal, SY; Kirciman, E; Ozalp, G; Yoldas, TK, 2004)
"To evaluate the efficacy of gabapentin for the treatment of uremic pruritus (UP)."7.74Role of gabapentin in the treatment of uremic pruritus. ( Gommer, J; Scates, AC; Vila, T, 2008)
"Gabapentin is a promising and a well-tolerated treatment option for patients with UP."6.82Gabapentin: A promising therapy for uremic pruritus in hemodialysis patients: A randomized-controlled trial and review of literature. ( Abdelkhalik, Z; Alkot, R; Eldesouky, F; Farag, F; Nofal, A; Nofal, E, 2016)
"Gabapentin is an effective drug in the management of neuropathic pain."6.73Gabapentin: a promising drug for the treatment of uremic pruritus. ( Harandi, AA; Khanbabapour, S; Mohseni, M; Naini, AE; Seirafiyan, S; Shahidi, S, 2007)
"Uremic pruritus is one of the most prevalent and bothersome dermatologic symptoms in patients with end-stage renal disease."6.66Gabapentin for uremic pruritus: a systematic review of randomized controlled trials. ( Castillo, RL; Dofitas, BL; Eusebio-Alpapara, KMV, 2020)
"Gabapentin and doxepin are well-known treatments of uremic pruritus in hemodialysis patients but no head-to-head studies were conducted to date."5.34Comparison of gabapentin and doxepin in the management of uremic pruritus: A randomized crossover clinical trial. ( Ammoury, A; Bachour, J; Haber, R; Habr, L; Joubran, N; Khoury, F; Maacaron, T; Salloum, A, 2020)
" dexchlorpheniramine in reducing uremic pruritus."5.27Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial. ( Abbade, LP; Gobo-Oliveira, M; Miot, HA; Ogata, MS; Pigari, VG; Ponce, D, 2018)
"Gabapentin relieved itching in 47 patients (66%)."5.16Uraemic pruritus: relief of itching by gabapentin and pregabalin. ( Baharani, J; Dasgupta, I; Rayner, H; Smith, S; Suresh, V, 2012)
"Desloratadine provides significant relief of uremic pruritus compared with no therapy."5.16Uremic pruritus in hemodialysis patients: treatment with desloratidine versus gabapentin. ( Barrón, B; Lauxmann, JE; Marquez, D; Martinatto, C; Novoa, PA; Orías, M; Peixoto, AJ; Ramonda, C; Romero, CA; Vukelic, VL, 2012)
"Gabapentin is an effective agent in treating uremic pruritus."5.14Gabapentin and uremic pruritus in hemodialysis patients. ( Eskandari, D; Ganji, MR; Khashayar, P; Meysamie, AP; Razeghi, E; Togha, M, 2009)
"Our study shows that gabapentin is safe and effective for treating uraemic pruritus in haemodialysis patients."5.11Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. ( Celiker, H; Gunal, AI; Gunal, SY; Kirciman, E; Ozalp, G; Yoldas, TK, 2004)
"Despite the acknowledged importance of uremic pruritus to patients, with the exception of gabapentin, the current evidence for treatments is weak."4.95Treatment of Uremic Pruritus: A Systematic Review. ( Askin, N; Bohm, C; Komenda, P; Lerner, B; Rigatto, C; Shaw, J; Simonsen, E; Tangri, N, 2017)
"To evaluate the efficacy of gabapentin for the treatment of uremic pruritus (UP)."3.74Role of gabapentin in the treatment of uremic pruritus. ( Gommer, J; Scates, AC; Vila, T, 2008)
"Gabapentin is a promising and a well-tolerated treatment option for patients with UP."2.82Gabapentin: A promising therapy for uremic pruritus in hemodialysis patients: A randomized-controlled trial and review of literature. ( Abdelkhalik, Z; Alkot, R; Eldesouky, F; Farag, F; Nofal, A; Nofal, E, 2016)
"Gabapentin is an effective drug in the management of neuropathic pain."2.73Gabapentin: a promising drug for the treatment of uremic pruritus. ( Harandi, AA; Khanbabapour, S; Mohseni, M; Naini, AE; Seirafiyan, S; Shahidi, S, 2007)
"Uremic pruritus is one of the most prevalent and bothersome dermatologic symptoms in patients with end-stage renal disease."2.66Gabapentin for uremic pruritus: a systematic review of randomized controlled trials. ( Castillo, RL; Dofitas, BL; Eusebio-Alpapara, KMV, 2020)
" The efficacy of MMF as an immunosuppressant and long-term safety in cats of this dosage regimen is unknown."2.61 ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"Gabapentin was used by 45% as first-, second-, or third-line treatment."1.46International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis. ( Bieber, BA; Ecder, T; Graham-Brown, M; Hasegawa, T; Kleophas, W; Larkina, M; Pisoni, RL; Rayner, HC; Robinson, BM; Tentori, F; van der Veer, SN; Wang, M, 2017)
" The adverse effects of gabapentin seem to vary from person to person and should be viewed with a high degree of suspicion, especially in patients taking this drug at the beginning."1.35Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia. ( Chen, CC; Chong, CF; Hung, TY; Seow, VK; Wang, TL, 2008)

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (37.50)29.6817
2010's13 (54.17)24.3611
2020's2 (8.33)2.80

Authors

AuthorsStudies
Bobenko, AI1
Heller, S1
Schmitt, N1
Cherdtrakulkiat, R1
Lawung, R1
Nabu, S1
Tantimavanich, S1
Sinthupoom, N1
Prachayasittikul, S1
Prachayasittikul, V1
Zhang, B1
Wu, C1
Zhang, Z2
Yan, K1
Li, C2
Li, Y4
Li, L3
Zheng, C1
Xiao, Y1
He, D1
Zhao, F1
Su, JF1
Lun, SM1
Hou, YJ1
Duan, LJ1
Wang, NC1
Shen, FF1
Zhang, YW1
Gao, ZW1
Li, J5
Du, XJ1
Zhou, FY1
Yin, Z1
Zhu, J2
Yan, D1
Lou, H1
Yu, H1
Feng, C1
Wang, Z1
Wang, Y4
Hu, X1
Li, Z2
Shen, Y1
Hu, D1
Chen, H1
Wu, X1
Duan, Y1
Zhi, D1
Zou, M2
Zhao, Z1
Zhang, X2
Yang, X2
Zhang, J2
Wang, H1
Popović, KJ1
Popović, DJ1
Miljković, D1
Lalošević, D1
Čapo, I1
Popović, JK1
Liu, M1
Song, H2
Xing, Z1
Lu, G1
Chen, D1
Valentini, AM1
Di Pinto, F1
Coletta, S1
Guerra, V1
Armentano, R1
Caruso, ML1
Gong, J1
Wang, N1
Bian, L1
Wang, M2
Ye, M1
Wen, N1
Fu, M1
Fan, W1
Meng, Y1
Dong, G1
Lin, XH1
Liu, HH1
Gao, DM1
Cui, JF1
Ren, ZG1
Chen, RX1
Önal, B1
Özen, D1
Demir, B1
Akkan, AG1
Özyazgan, S1
Payette, G1
Geoffroy, V1
Martineau, C1
Villemur, R1
Jameel, T1
Baig, M1
Gazzaz, ZJ1
Tashkandi, JM1
Al Alhareth, NS1
Khan, SA1
Butt, NS1
Wang, J2
Geng, Y1
Zhang, Y3
Wang, X2
Liu, J2
Basit, A1
Miao, T1
Liu, W1
Jiang, W1
Yu, ZY1
Wu, L2
Qu, B1
Sun, JX1
Cai, AL1
Xie, LM1
Groeneveld, J1
Ho, SL1
Mackensen, A1
Mohtadi, M1
Laepple, T1
Genovesi, S1
Nava, E1
Bartolucci, C1
Severi, S1
Vincenti, A1
Contaldo, G1
Bigatti, G1
Ciurlino, D1
Bertoli, SV1
Slovak, JE1
Hwang, JK1
Rivera, SM1
Villarino, NF1
Li, S1
Cao, G1
Ling, M1
Ji, J1
Zhao, D1
Sha, Y1
Gao, X1
Liang, C2
Guo, Q1
Zhou, C1
Ma, Z1
Xu, J1
Wang, C1
Zhao, W1
Xia, X1
Jiang, Y1
Peng, J1
Jia, Z1
Li, F1
Chen, X2
Mo, J1
Zhang, S2
Li, X1
Huang, T1
Zhu, Q1
Wang, S1
Ge, RS1
Fortunato, G1
Lin, J2
Agarwal, PK1
Kohen, A1
Singh, P1
Cheatum, CM1
Zhu, D1
Hayman, A1
Kebede, B1
Stewart, I1
Chen, G1
Frew, R1
Guo, X1
Gong, Q1
Borowiec, J1
Han, S1
Zhang, M1
Willis, M1
Kreouzis, T1
Yu, K1
Chirvony, VS1
Sekerbayev, KS1
Pérez-Del-Rey, D1
Martínez-Pastor, JP1
Palazon, F1
Boix, PP1
Taurbayev, TI1
Sessolo, M1
Bolink, HJ1
Lu, M1
Lan, Y1
Xiao, J1
Song, M1
Chen, C1
Huang, Q1
Cao, Y1
Ho, CT1
Qi, B1
Wang, Q1
Zhang, W1
Fang, L1
Xie, CL1
Chen, R1
Yang, S1
Xia, JM1
Zhang, GY1
Chen, CH1
Yang, XW1
Domenech-Ximenos, B1
Garza, MS1
Prat-González, S1
Sepúlveda-Martínez, Á1
Crispi, F1
Perea, RJ1
Garcia-Alvarez, A1
Sitges, M1
Kalumpha, M1
Guyo, U1
Zinyama, NP1
Vakira, FM1
Nyamunda, BC1
Varga, M1
Drácz, L1
Kolbenheyer, E1
Varga, F1
Patai, ÁV1
Solymosi, N1
Patai, Á1
Kiss, J1
Gaál, V1
Nyul, Z1
Mosdósi, B1
Valdez, M1
Moosavi, L1
Heidari, A1
Novakovic-Agopian, T1
Kornblith, E1
Abrams, G1
McQuaid, JR1
Posecion, L1
Burciaga, J1
D'Esposito, M1
Chen, AJW1
Samy El Gendy, NM1
Wesolowska, P1
Georg, D1
Lechner, W1
Kazantsev, P1
Bokulic, T1
Tedgren, AC1
Adolfsson, E1
Campos, AM1
Alves, VGL1
Suming, L1
Hao, W1
Ekendahl, D1
Koniarova, I1
Bulski, W1
Chelminski, K1
Samper, JLA1
Vinatha, SP1
Rakshit, S1
Siri, S1
Tomsejm, M1
Tenhunen, M1
Povall, J1
Kry, SF1
Followill, DS1
Thwaites, DI1
Izewska, J1
Kang, JH1
Yoon, Y1
Song, J1
Van de Winckel, A1
Gauthier, L1
Chao, CT1
Lee, YH1
Li, CM1
Han, DS1
Huang, JW1
Huang, KC1
Ni, L1
Güttinger, R1
Triana, CA1
Spingler, B1
Baldridge, KK1
Patzke, GR1
Shen, X1
Wang, B1
Xie, S1
Deng, W1
Wu, D1
Zhang, Q1
Voskamp, BJ1
Peelen, MJCS1
Ravelli, ACJ1
van der Lee, R1
Mol, BWJ1
Pajkrt, E1
Ganzevoort, W1
Kazemier, BM1
Tibrewala, R1
Bahroos, E1
Mehrabian, H1
Foreman, SC1
Link, TM1
Pedoia, V1
Majumdar, S1
Jablonski, CL1
Leonard, C1
Salo, P1
Krawetz, RJ1
Yoon, N1
Hong, SN1
Cho, JG1
Jeong, HK1
Lee, KH1
Park, HW1
Barman, S1
Konai, MM1
Samaddar, S1
Haldar, J1
Mohamed, HSH1
Li, CF1
Hu, ZY1
Deng, Z1
Chen, LH1
Su, BL1
Chu, K1
Liu, YP1
Li, YB1
Zhang, H1
Xu, C1
Zou, Z1
Wu, Z1
Xia, Y1
Zhao, P1
Wang, HT1
de Biase, S1
Pellitteri, G1
Gigli, GL1
Valente, M1
Rossi, GM1
Corradini, M1
Blanco, V1
Mattei, S1
Fiaccadori, E1
Vaglio, A4
Manenti, L4
Eusebio-Alpapara, KMV1
Castillo, RL1
Dofitas, BL1
Haber, R1
Bachour, J1
Salloum, A1
Maacaron, T1
Khoury, F1
Habr, L1
Ammoury, A1
Joubran, N1
Simonsen, E1
Komenda, P1
Lerner, B1
Askin, N1
Bohm, C1
Shaw, J1
Tangri, N1
Rigatto, C1
Rayner, HC1
Larkina, M1
Graham-Brown, M1
van der Veer, SN1
Ecder, T1
Hasegawa, T1
Kleophas, W1
Bieber, BA1
Tentori, F1
Robinson, BM1
Pisoni, RL1
Gobo-Oliveira, M1
Pigari, VG1
Ogata, MS1
Miot, HA1
Ponce, D1
Abbade, LP1
Rayner, H1
Baharani, J1
Smith, S1
Suresh, V1
Dasgupta, I1
Mettang, T2
Kremer, AE1
Yong, AS1
Lee, KY1
Nofal, E1
Farag, F1
Nofal, A1
Eldesouky, F1
Alkot, R1
Abdelkhalik, Z1
Pongcharoen, P1
Fleischer, AB1
Razeghi, E1
Eskandari, D1
Ganji, MR1
Meysamie, AP1
Togha, M1
Khashayar, P1
Liu, JH1
Yang, YW1
Huang, CC1
Marquez, D1
Ramonda, C1
Lauxmann, JE1
Romero, CA1
Vukelic, VL1
Martinatto, C1
Barrón, B1
Novoa, PA1
Peixoto, AJ1
Orías, M1
Gunal, AI1
Ozalp, G1
Yoldas, TK1
Gunal, SY1
Kirciman, E1
Celiker, H1
Molnar, MZ1
Novak, M1
Mucsi, I1
Naini, AE1
Harandi, AA1
Khanbabapour, S1
Shahidi, S1
Seirafiyan, S1
Mohseni, M1
Borgatti, PP1
Hung, TY1
Seow, VK1
Chong, CF1
Wang, TL1
Chen, CC1
Vila, T1
Gommer, J1
Scates, AC1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Treatment Effect of Chinese Medicine Formula on Uremic Pruritus[NCT04650750]Early Phase 160 participants (Anticipated)Interventional2020-12-01Not yet recruiting
Prospective Randomized Study Evaluating the Efficacy of the Spherical Absorptive Carbon AST-120 in Hemodialysis Patients With Uremic Pruritus..[NCT04639674]Phase 4100 participants (Actual)Interventional2020-07-02Completed
Effectiveness of Sertraline in Alleviating Uremic Pruritis in Hemodialysis Patients[NCT05341843]Phase 260 participants (Actual)Interventional2022-05-01Completed
Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial[NCT02646020]Phase 2138 participants (Actual)Interventional2015-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

7 reviews available for gabapentin and Uremia

ArticleYear
    Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227

    Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P

2019
Gabapentin for uremic pruritus: a systematic review of randomized controlled trials.
    International journal of dermatology, 2020, Volume: 59, Issue:4

    Topics: Dizziness; Gabapentin; Humans; Incidence; Kidney Failure, Chronic; Pruritus; Randomized Controlled T

2020
Treatment of Uremic Pruritus: A Systematic Review.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:5

    Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom

2017
Treatment of Uremic Pruritus: A Systematic Review.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:5

    Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom

2017
Treatment of Uremic Pruritus: A Systematic Review.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:5

    Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom

2017
Treatment of Uremic Pruritus: A Systematic Review.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:5

    Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom

2017
Uremic pruritus.
    Kidney international, 2015, Volume: 87, Issue:4

    Topics: Acupuncture Therapy; Amines; Anti-Inflammatory Agents; Calcium Channel Blockers; Cyclohexanecarboxyl

2015
Itch Management: Systemic Agents.
    Current problems in dermatology, 2016, Volume: 50

    Topics: Amines; Analgesics; Analgesics, Opioid; Anion Exchange Resins; Antidepressive Agents; Aprepitant; Ch

2016
Uremic Itch Management.
    Current problems in dermatology, 2016, Volume: 50

    Topics: Acupuncture Therapy; Amines; Analgesics, Opioid; Anticonvulsants; Calcineurin Inhibitors; Cyclohexan

2016
Management of restless legs syndrome in patients on dialysis.
    Drugs, 2006, Volume: 66, Issue:5

    Topics: Amines; Anticonvulsants; Benzothiazoles; Clonazepam; Cyclohexanecarboxylic Acids; Dopamine Agents; G

2006

Trials

9 trials available for gabapentin and Uremia

ArticleYear
Randomized trial of two after-dialysis gabapentin regimens for severe uremic pruritus in hemodialysis patients.
    Internal and emergency medicine, 2019, Volume: 14, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Double-Blind Method; Female; Gabapentin; Humans; Male; M

2019
Comparison of gabapentin and doxepin in the management of uremic pruritus: A randomized crossover clinical trial.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Double-Blind Method; Doxepin; Gabapentin; Histamine Antagonists; Humans; Pruritus; Quality of Life;

2020
Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial.
    European journal of dermatology : EJD, 2018, Aug-01, Volume: 28, Issue:4

    Topics: Aged; Chlorpheniramine; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Gabapentin;

2018
Uraemic pruritus: relief of itching by gabapentin and pregabalin.
    Nephron. Clinical practice, 2012, Volume: 122, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Comorbidity; Cyclohexanecarboxylic Acids; Dose-R

2012
Gabapentin: A promising therapy for uremic pruritus in hemodialysis patients: A randomized-controlled trial and review of literature.
    The Journal of dermatological treatment, 2016, Volume: 27, Issue:6

    Topics: Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Double-Blind Method; Excitatory Amino Acid Antagon

2016
Gabapentin and uremic pruritus in hemodialysis patients.
    Renal failure, 2009, Volume: 31, Issue:2

    Topics: Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gaba

2009
Uremic pruritus in hemodialysis patients: treatment with desloratidine versus gabapentin.
    Jornal brasileiro de nefrologia, 2012, Volume: 34, Issue:2

    Topics: Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Histam

2012
Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2004, Volume: 19, Issue:12

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans

2004
Gabapentin: a promising drug for the treatment of uremic pruritus.
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2007, Volume: 18, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Amines; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Ga

2007

Other Studies

8 other studies available for gabapentin and Uremia

ArticleYear
International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
    Clinical journal of the American Society of Nephrology : CJASN, 2017, Dec-07, Volume: 12, Issue:12

    Topics: Aged; Aged, 80 and over; Amines; Antipruritics; Chronic Disease; Cyclohexanecarboxylic Acids; Female

2017
International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
    Clinical journal of the American Society of Nephrology : CJASN, 2017, Dec-07, Volume: 12, Issue:12

    Topics: Aged; Aged, 80 and over; Amines; Antipruritics; Chronic Disease; Cyclohexanecarboxylic Acids; Female

2017
International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
    Clinical journal of the American Society of Nephrology : CJASN, 2017, Dec-07, Volume: 12, Issue:12

    Topics: Aged; Aged, 80 and over; Amines; Antipruritics; Chronic Disease; Cyclohexanecarboxylic Acids; Female

2017
International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
    Clinical journal of the American Society of Nephrology : CJASN, 2017, Dec-07, Volume: 12, Issue:12

    Topics: Aged; Aged, 80 and over; Amines; Antipruritics; Chronic Disease; Cyclohexanecarboxylic Acids; Female

2017
Uremic pruritus is improved by gabapentin.
    International journal of dermatology, 2014, Volume: 53, Issue:9

    Topics: Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric A

2014
Advancing the scheduled time of hemodialysis is benificial for maintenance hemodialysis patients with gabapentin intolerance.
    Blood purification, 2010, Volume: 29, Issue:4

    Topics: Aged; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Amino

2010
Gabapentin for uraemic pruritus.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:6

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Prurit

2005
Gabapentin use in chronic uraemic itch is in line with emerging pathogenetic hypothesis.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:12

    Topics: Amines; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; P

2007
Gabapentin as a therapeutic option in uremic pruritus.
    Kidney international, 2008, Volume: 73, Issue:4

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Prurit

2008
Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia.
    Emergency medicine journal : EMJ, 2008, Volume: 25, Issue:3

    Topics: Amines; Anticonvulsants; Consciousness Disorders; Cyclohexanecarboxylic Acids; Diagnosis, Differenti

2008
Role of gabapentin in the treatment of uremic pruritus.
    The Annals of pharmacotherapy, 2008, Volume: 42, Issue:7

    Topics: Amines; Antipruritics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Kid

2008